标题/作者	年份
The updated landscape of tumor microenvironment and drug repurposing MZ Jin, WL Jin Signal transduction and targeted therapy 5 (1), 166	2020
Exosomal miRNAs in tumor microenvironment S Tan, L Xia, P Yi, Y Han, L Tang, Q Pan, Y Tian, S Rao, L Oyang, J Liang, ... Journal of Experimental & Clinical Cancer Research 39, 1-15	2020
Neoadjuvant treatment for triple negative breast cancer: recent progresses and challenges JS Lee, SE Yost, Y Yuan Cancers 12 (6), 1404	2020
Ivermectin, a potential anticancer drug derived from an antiparasitic drug M Tang, X Hu, Y Wang, X Yao, W Zhang, C Yu, F Cheng, J Li, Q Fang Pharmacological research 163, 105207	2021
Triple-negative breast cancer: a brief review about epidemiology, risk factors, signaling pathways, treatment and role of artificial intelligence NM Almansour Frontiers in Molecular Biosciences 9, 836417	2022
The tumor microenvironment as driver of stemness and therapeutic resistance in breast cancer: New challenges and therapeutic opportunities U Mehraj, RA Ganai, MA Macha, A Hamid, MA Zargar, AA Bhat, ... Cellular Oncology, 1-21	2021
Fibronectin-targeting and cathepsin B-activatable theranostic nanoprobe for MR/fluorescence imaging and enhanced photodynamic therapy for triple negative breast cancer Y Wang, L Jiang, Y Zhang, Y Lu, J Li, H Wang, D Yao, D Wang ACS applied materials & interfaces 12 (30), 33564-33574	2020
Triple negative breast cancer and non-small cell lung cancer: Clinical challenges and nano-formulation approaches S Ghosh, A Javia, S Shetty, D Bardoliwala, K Maiti, S Banerjee, ... Journal of Controlled Release 337, 27-58	2021
The research progress of antiangiogenic therapy, immune therapy and tumor microenvironment H Hu, Y Chen, S Tan, S Wu, Y Huang, S Fu, F Luo, J He Frontiers in immunology 13, 802846	2022
Patient-derived organoids in precision medicine: drug screening, organoid-on-a-chip and living organoid biobank Z Zhou, L Cong, X Cong Frontiers in Oncology 11, 762184	2021
Immunotherapy in breast cancer: when, how, and what challenges? B Henriques, F Mendes, D Martins Biomedicines 9 (11), 1687	2021
Prognostic analysis of cuproptosis-related gene in triple-negative breast cancer S Sha, L Si, X Wu, Y Chen, H Xiong, Y Xu, W Liu, H Mei, T Wang, M Li Frontiers in immunology 13, 922780	2022
Breast cancer targeting of a drug delivery system through postsynthetic modification of curcumin@ N3-bio-MOF-100 via click chemistry RC Alves, ZM Schulte, MT Luiz, P Bento da Silva, RCG Frem, NL Rosi, ... Inorganic Chemistry 60 (16), 11739-11744	2021
Epigenetic alterations in triple-negative breast cancer—The critical role of extracellular matrix V Zolota, V Tzelepi, Z Piperigkou, H Kourea, E Papakonstantinou, ... Cancers 13 (4), 713	2021
The characteristics of tumor microenvironment in triple negative breast cancer Y Fan, S He Cancer management and research, 1-17	2022
Reactive oxygen species (ROS): Critical roles in breast tumor microenvironment RR Malla, N Surepalli, B Farran, SV Malhotra, GP Nagaraju Critical Reviews in Oncology/Hematology 160, 103285	2021
Nuclear factor-κB signaling inhibitors revert multidrug-resistance in breast cancer cells SM Abdin, MF Tolba, DM Zaher, HA Omar Chemico-Biological Interactions 340, 109450	2021
Sphingomyelin synthase 2 facilitates M2-like macrophage polarization and tumor progression in a mouse model of triple-negative breast cancer Y Deng, J Hu, S He, B Lou, T Ding, J Yang, M Mo, D Ye, L Zhou, X Jiang, ... Acta Pharmacologica Sinica 42 (1), 149-159	2021
Understanding the role of innate immune cells and identifying genes in breast cancer microenvironment I Shihab, BA Khalil, NM Elemam, IY Hachim, MY Hachim, RA Hamoudi, ... Cancers 12 (8), 2226	2020
Immune-related biomarkers in triple-negative breast cancer J Zhang, Q Tian, M Zhang, H Wang, L Wu, J Yang Breast Cancer 28, 792-805	2021

1 - 20

计算机程序会自动估算并确定日期和引用次数。